Novo Holdings

Bispecific antibodies
#Alentis Therapeutics #Antibody drug conjugate (ADC) #Biotechnology #Collaboration #Financing #Novo Holdings #Solid tumours

Successful collaboration to advance ADCs for solid tumours 

Novo Holdings has co-led a $181.4 million Series D financing in Alentis Therapeutics, a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines.  This financing will enable Alentis to begin Phase I/II trials for two first-in-class ADCs: ALE.P02, which… Read More

#Business & Investment #News

GBP pound sterling funding
#Biopharmaceuticals #Biotechnology #Finance #Investment #mRNA #Novo Holdings #Oxford Nanopore Technologies

Investing in a new generation of molecular analysis technology 

Novo Holdings has announced a £5 million investment in Oxford Nanopore Technologies as part of an equity issue and intends to add to this investment over time, with further purchases in the secondary market, subject to availability and price (among other factors).  Oxford Nanopore has developed a… Read More

#Business & Investment #News